TB Research

Evaluating the impact of COVID-19 or SARS-CoV-2 vaccination on TB infection testing in the context of TB elimination

Dina Visca, Rosella Centis, Lia D’Ambrosio, Antonio Spanevello, Linda Petrone, Giovanni Battista Migliori, Delia Goletti

The International Journal of Tuberculosis and Lung Disease · 2025-06

Abstract

<sec><title>OBJECTIVES</title>The impact of COVID-19 and SARS-CoV-2-vaccination on interferon-gamma release assay (IGRA) indeterminate results is unclear. This mini-review aims to examine whether COVID-19 or SARS-CoV-2-vaccination affects the accuracy of IGRAs by increasing the indeterminate rate.</sec><sec><title>METHODS</title>Non-systematic literature review based on a PubMed search using specific keywords, including various combinations of 'TB', 'quantiferon', 'indeterminate or negative results' and 'covid' without any time limits.</sec><sec><title>RESULTS</title>A systematic review found an overall pooled effect size (equivalent to the indeterminate results) of 0.26 (95% confidence: 0.205-0.32) for QuantiFERON TB Plus (QFT-TB) with a mean true effect size of 0.26 (95% prediction interval: 0.11-0.5), and other studies confirmed the link with disease severity. SARS-CoV-2 vaccination does not affect IGRA interpretation.</sec><sec><title>CONCLUSIONS</title>The use of IGRAs is not significantly affected by the COVID-19 pandemic or vaccinations, except in a small number of severe cases observed during the pandemic's peak. IGRAs' reliability remains consistent with their pre-pandemic performance.</sec>.

MeSH terms

  • Medicine
  • Vaccination
  • Coronavirus disease 2019 (COVID-19)
  • Context (archaeology)
  • Confidence interval
  • QuantiFERON
  • Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
  • Pandemic
  • Indeterminate
  • Immunology